BW-00112 / Argo Biopharma - LARVOL DELTA

BW-00112 targeting ANGPTL3 results in prolonged reductions in plasma triglycerides, LDL-C, and remnant-C in Chinese healthy subjects (ESC-WCC 2025) - "Substantial PD effects were observed with single subcutaneous doses of BW-00112 ranging from 150 mg to 600 mg, including reductions in ANGPTL3, triglycerides, LDL-C, ApoB, non-HDL-C, and remnant-C. No big difference was observed on safety, PK, and PD in Australian and Chinese healthy subjects."

Clinical • Cardiovascular • Dyslipidemia • ANGPTL3 • APOB • LPL

A Study in Patients With Mixed Dyslipidemia (clinicaltrials.gov) - P2 | N=132 | Recruiting | Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. | Active, not recruiting ➔ Recruiting | Trial completion date: Oct 2025 ➔ Mar 2028 | Trial primary completion date: Jul 2025 ➔ Jun 2026

Enrollment open • Trial completion date • Trial primary completion date • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia

A Study in Patients With Mixed Dyslipidemia (clinicaltrials.gov) - P2 | N=132 | Active, not recruiting | Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia

BW-00112 targeting ANGPTL3 results in prolonged reductions in plasma triglycerides, LDL-C, and remnant-C in human subjects (NLA 2025) - "Conclusions BW-00112 was generally well tolerated when administered subcutaneously as a single dose ranging from 50 mg to 600 mg. Notable PD effects were observed with single subcutaneous doses of BW-00112 ranging from 150 mg to 600 mg, including reductions in ANGPTL3, triglycerides, LDL-C, ApoB, Non-HDL-C, and remnant-C."

Clinical • Cardiovascular • Dermatology • Dyslipidemia • Metabolic Disorders • ANGPTL3 • APOB • LPL

A Study in Patients with Mixed Dyslipidemia (clinicaltrials.gov) - P2 | N=132 | Recruiting | Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Dyslipidemia • Metabolic Disorders • Mixed Hyperlipidemia

A Study in Patients With Mixed Dyslipidemia (clinicaltrials.gov) - P2 | N=132 | Not yet recruiting | Sponsor: Argo Biopharmaceutical Co., Ltd.

New P2 trial • Dyslipidemia • Metabolic Disorders

A Study to Evaluate BW-00112 in Adult Subjects (ANZCTR) - P1 | N=32 | Completed | Sponsor: ARGO BIOPHARMA AUSTRALIA PTY LTD | Recruiting ➔ Completed

Trial completion • Dyslipidemia • APOA1 • APOB

A Study to Evaluate BW-00112 in Adult Subjects (ANZCTR) - P1 | N=32 | Recruiting | Sponsor: ARGO BIOPHARMA AUSTRALIA PTY LTD | Initiation date: Jan 2000 ➔ Jan 2023

Trial initiation date • Dyslipidemia • APOA1 • APOB